FDA Real-Time Clinical Trials pilot announced — neurotech adaptive trial designs now eligible for accelerated feedback
Summary
HHS Secretary Marty Makary announced the FDA Real-Time Clinical Trials pilot program in April 2026, enabling companies to receive real-time regulatory feedback as clinical trial data accumulates — rather than waiting for trial completion to begin FDA dialogue. Neurotech Notables #53 flagged this as significant for the neurotech sector, where adaptive BCI trial designs and closed-loop algorithm updates during trials have historically created regulatory uncertainty. Real-time feedback enables BCI companies to adjust study parameters, endpoints, and device algorithms with FDA guidance during the trial rather than after costly trial failures.
Why it matters
Real-time FDA feedback during clinical trials is transformative for BCI and neuromodulation companies developing "living devices" with AI algorithms designed to improve during use. Traditional FDA review assumes a static, finalized device at submission — BCI devices that improve through use challenge this paradigm. Real-time trial feedback enables FDA to develop familiarity with adaptive BCI systems during the trial rather than only at PMA submission, removing a major source of regulatory uncertainty for AI-adaptive neurotech.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial